Published May 29, 2020
BUFFALO, N.Y. — Maya Chilbert, PharmD ’17, clinical assistant professor, pharmacy practice, is the recipient of the American College of Clinical Pharmacy (ACCP) Cardiology Practice and Research Network seed grant.
The grant, titled “Triple therapy with rivaroxaban vs apixaban,” will determine the safety and effectiveness of anti-clotting triple therapy regimens that combine a direct acting oral anticoagulant (rivaroxaban or apixaban), a P2Y12 inhibitor, and aspirin. Treatment effects of these triple therapy regimens will be compared in patients with atrial fibrillation or venous thromboembolism. The primary outcome will compare bleeding rates in the apixaban versus rivaroxaban treatment groups, and the secondary outcome will compare a composite of myocardial infarction, stroke, systemic embolization and all-cause death.
Patients will be included from two large health systems in New York State: Montefiore Medical Center in New York City and Kaleida Health Systems in the Buffalo-Niagara region.
The results of this study will provide guidance to practitioners for selecting the best strategy to balance safety and effectiveness for triple therapy regimens. It will also identify high risk patient populations and concurrent treatments.
Co-investigators on the grant include David Jacobs, PharmD ’11, PhD ’18, assistant professor, pharmacy practice; Ashley Woodruff, PharmD’ 09, clinical associate professor, pharmacy practice; Mark Sinnet, BS ’83 & PharmD ’87, director, clinical and educational pharmacy services, Montefiore Medical Center; and Pavel Goriacko, clinical pharmacy manager, clinical care, Montefiore Medical Center.
The ACCP Cardiology Practice and Research Network advances the pharmacotherapy of cardiovascular disorders through the promotion of excellence in education, research, and clinical practice by enhancing the knowledge, skills, and productivity of its members.